je.st
news
Celladon's Failure Shouldn't Trickle Down To Other Gene Therapy Biotechs
2015-05-27 16:26:47| Biotech - Topix.net
Spark Therapeutics is working on restoring vision for children so they may function properly and meets a big unmet medical need. Bluebird Bio has shown positive preliminary results that are showing to reduce the need for blood transfusions in beta-thalassemia and sickle-cell disease.
Tags: failure
therapy
gene
trickle
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||